Siemens ADVIA 2120, Operator'S Manual, Page: 396 / 477

Regulatory Information 9-55
By providing a direct measure of the hemoglobin content of reticulocytes, the
CHr Assay gives health care professionals a new sensitive tool for the early
detection of functional iron deficiency and provides additional information that
can be used in managing the iron requirements for rHuEPO therapy.
Bibliography
Savage RA, Skoog DD, and Rabinovich A: Analytical inaccuracy and
imprecision in reticulocyte counting: A preliminary report from the College of
American Pathologist’s reticulocyte project.
Blood Cells 11
:97-112 (1985)
Brugnara C, Colella G, Cremins J, Langley R, Schneider T, Rutherford C,
Goldberg M.: Effects of subcutaneous recombinant human erythropoietin in
normal subjects: Development of decreased reticulocyte hemoglobin content and
iron-deficient erythropoiesis.
J Lab Clin Med 123
:660-667 (1994)
Fishbane S,
et al
: Reticulocyte hemoglobin content in the evaluation of iron
status in hemodialysis patients.
Kidney Intl 52
:217-222 (1997)
Reagents
The following ready-to-use reagents are required to perform the Reticulocyte
method and maintain the ADVIA 2120/2120i Hematology System:
ADVIA 120 autoRETIC
ADVIA 120 SHEATH/RINSE
ADVIA 120 EZ KLEEN
ADVIA 120 DEFOAMER
ADVIA 120 autoRETIC
Product Number Contents Amount (mL)
04296794 T01-3622-54 autoRETIC 4 x 820 mL
- T01-3622-01 autoRETIC 820 mL
ADVIA 120 autoRETIC contains:
Oxazine 750, 11.4 mg/L
Buffer
N-Tetradecyl-N,N-dimethyl-3-ammonio-1-
propane sulfonate, 0.023 mmol/L
N,N-dimethylformamide, 0.38%
For
in vitro
diagnostic use.